These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19580030)

  • 1. Costs of alien invasive species in Sweden.
    Gren IM; Isacs L; Carlsson M
    Ambio; 2009 May; 38(3):135-40. PubMed ID: 19580030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of radiotherapy in Sweden.
    Acta Oncol; 1996; 35 Suppl 6():57-71. PubMed ID: 9154086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AIDS epidemic in Sweden: estimates of costs, 1986, 1987 and 1990.
    Herlitz C; Brorsson B
    Scand J Soc Med; 1989; 17(1):39-48. PubMed ID: 2496463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The costs of treating hypertension in Sweden. An empirical investigation in primary health care.
    Johannesson M; Borgquist L; Jönsson B
    Scand J Prim Health Care; 1991 Sep; 9(3):155-60. PubMed ID: 1754746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of COPD in Sweden according to disease severity.
    Jansson SA; Andersson F; Borg S; Ericsson A; Jönsson E; Lundbäck B
    Chest; 2002 Dec; 122(6):1994-2002. PubMed ID: 12475838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
    Hagell P; Nordling S; Reimer J; Grabowski M; Persson U
    Mov Disord; 2002 Nov; 17(6):1213-20. PubMed ID: 12465059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug and treatment costs in Parkinson's disease patients in Sweden.
    Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
    Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodiversity on Swedish pastures: estimating biodiversity production costs.
    Nilsson FO
    J Environ Manage; 2009 Jan; 90(1):131-43. PubMed ID: 18079049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N; Tambour M; Henriksson F; Fredrikson S
    J Med Econ; 2013; 16(3):349-57. PubMed ID: 23211038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
    Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O
    Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economic costs of COPD in Sweden by disease severity--has it changed during a ten years period?
    Jansson SA; Backman H; Stenling A; Lindberg A; Rönmark E; Lundbäck B
    Respir Med; 2013 Dec; 107(12):1931-8. PubMed ID: 23910072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of breast cancer in Sweden in 2002.
    Lidgren M; Wilking N; Jönsson B
    Eur J Health Econ; 2007 Mar; 8(1):5-15. PubMed ID: 17216424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Cost of Global Biodiversity and Conservation Knowledge.
    Juffe-Bignoli D; Brooks TM; Butchart SH; Jenkins RB; Boe K; Hoffmann M; Angulo A; Bachman S; Böhm M; Brummitt N; Carpenter KE; Comer PJ; Cox N; Cuttelod A; Darwall WR; Di Marco M; Fishpool LD; Goettsch B; Heath M; Hilton-Taylor C; Hutton J; Johnson T; Joolia A; Keith DA; Langhammer PF; Luedtke J; Nic Lughadha E; Lutz M; May I; Miller RM; Oliveira-Miranda MA; Parr M; Pollock CM; Ralph G; Rodríguez JP; Rondinini C; Smart J; Stuart S; Symes A; Tordoff AW; Woodley S; Young B; Kingston N
    PLoS One; 2016; 11(8):e0160640. PubMed ID: 27529491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights.
    Norrlid H; Dahm P; Tennvall GR
    Scand J Pain; 2015 Jan; 6(1):24-30. PubMed ID: 29911578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic consequences of asthma among adults in Sweden.
    Jansson SA; Rönmark E; Forsberg B; Löfgren C; Lindberg A; Lundbäck B
    Respir Med; 2007 Nov; 101(11):2263-70. PubMed ID: 17689234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs associated with sharps injuries in the Swedish health care setting and potential cost savings from needle-stick prevention devices with needle and syringe.
    Glenngård AH; Persson U
    Scand J Infect Dis; 2009; 41(4):296-302. PubMed ID: 19229763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
    Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
    Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does remediation save lives? - on the cost of cleaning up arsenic-contaminated sites in Sweden.
    Forslund J; Samakovlis E; Johansson MV; Barregard L
    Sci Total Environ; 2010 Jul; 408(16):3085-91. PubMed ID: 20439110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resource use and costs associated with different states of breast cancer.
    Lidgren M; Wilking N; Jönsson B; Rehnberg C
    Int J Technol Assess Health Care; 2007; 23(2):223-31. PubMed ID: 17493308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Participation, resource mobilization and financial incentives in community-based health promotion: an economic evaluation perspective from Sweden.
    Johansson PM; Eriksson LS; Sadigh S; Rehnberg C; Tillgren PE
    Health Promot Int; 2009 Jun; 24(2):177-84. PubMed ID: 19321496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.